Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Mayne Pharma Group ( (AU:MYX) ).
Mayne Pharma Group Limited announced a delay in the Foreign Investment Review Board’s decision regarding its acquisition by Cosette Pharmaceuticals, which may affect the timing of the Second Court Hearing initially scheduled for 22 October 2025. The company is assessing whether to reschedule the hearing and will update stakeholders accordingly, though shareholders are not required to take any action at this time.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals to provide safer and more accessible medicines. It is a leader in dermatology and women’s health in the United States and offers contract development and manufacturing services globally. With a 40-year history of innovation, Mayne Pharma has successfully developed and commercialized new oral drug delivery systems.
Average Trading Volume: 285,011
Technical Sentiment Signal: Buy
Current Market Cap: A$455M
For an in-depth examination of MYX stock, go to TipRanks’ Overview page.